Atara (in collaboration with MSK) will [​] continue, and will [​] cause MSK to continue, [​] the [[Unknown Identifier]] Phase 1 Clinical Trial in the manner outlined within the [[Unknown Identifier]] Plan and any other Phase 1 Clinical Trial relating to [[Unknown Identifier]] in the manner pre-agreed upon (including with respect to any financial terms) with Bayer. Atara will report on its activities under such Phase 1 Clinical Trial and results thereof both through written reports and through oral communication (including via the JSC), and shall provide Bayer deliverables of such activities and results, each with information, frequency, within the timelines and with a format as specified in the relevant [[Unknown Identifier]] Plan. This includes that Atara will submit to Bayer all Regulatory Documentation and all other study data relating to the [[Unknown Identifier]] Phase 1 Clinical Trial within due course, but in no event later than within [​] Business Days after such documents and data are received or generated by Atara. Upon request of Bayer, Atara will enable Bayer scientists to participate as observing members in any material development-related activities of Atara and to the extent that Atara has the right to do so, any material development-related activities of MSK, said participation being subject to MSK’s approval. Atara will [​] obtain such approval from MSK and will, upon Bayer’s written request, inform Bayer about the steps taken to obtain such MSK approval and the status of the approval process.

Development Responsibilities. Subject to the terms and conditions of this Agreement, including this Article 3 (Development) and Section 5.5 (Decision-Making; Escalation to Senior Officers), Lian will have sole authority to, at its own costs and expense, Develop the Licensed Product for the purpose of obtaining Regulatory Approval in the Field in the Territory. Lian will be responsible for the day-to-day implementation of any Development activities for which it (or any of its Affiliates) is assigned responsibility under this Agreement (including under the Development Plans) and will keep Lyra reasonably informed as to the progress of such activities in accordance with [Section 3.5(b)] (Reporting).

Allocation of Development Responsibilities. The Development Plan shall allocate Development responsibilities of the Compounds and Collaboration Products between the Parties as follows:

Development Responsibilities. Ovid shall be responsible for, and shall use Ovid Commercially Reasonable Efforts in connection with, the conduct of the Ovid Ongoing Trials. Licensee shall be responsible for the conduct of the Licensee Territory Development Activities, other than Additional Pivotal Study which shall be shared by the Parties as set forth in [Section 4.2(c)(ii)]. The Parties shall each be responsible for the conduct of the Joint Development Activities, and the allocation of such agreed responsibility therefore (including which Party shall be the Sponsor for each applicable Clinical Trial), shall be set forth in the Development Plan. Each Party shall have the operational responsibility and be the Sponsor for its own Independent Development Activities.

Responsibilities. The JSC’s responsibilities shall include, but not be limited to, the following functions:

Responsibilities. The CPC shall:

Development Responsibilities. Ovid shall be responsible for, and shall use Ovid Commercially Reasonable Efforts in connection with, the conduct of the Ovid Ongoing Trials. Licensee shall be responsible for the conduct of the Licensee Territory Development Activities, other than Additional Pivotal Study which shall be shared by the Parties as set forth in Section ​ = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both # not material and # would be competitively harmful if publicly disclosed.

Development Responsibilities. Unless the Parties agree in writing upon an alternate allocation of responsibility, FibroGen China shall be responsible for conducting the Clinical Trials under the Development Plan in accordance with GCP and all applicable laws and regulations. The Development Plan shall specify success criteria and a timetable for the completion of such Clinical Trials.

HFB Development Responsibilities. Subject to the terms of this Agreement, on an Option Program-by-Option Program basis prior to the Option Exercise Date with respect to such Option Program, HFB will conduct the Development activities with respect to each Option Program, ​. On a Licensed Program-by-Licensed Program basis, HFB will conduct solely those Development activities allocated to it under the applicable Work Plan for such Licensed Program, ​, subject to any agreed budget set forth in such Work Plan.

General Development Responsibilities. Except with respect to Research activities to be conducted by [[Merus:Organization]] pursuant to a Research Plan, Lilly shall be solely responsible for the Exploitation of Compounds and Products with respect to Lilly Target Pairs (or in the event Lilly pursues a Monospecific Compound, directed to each applicable Lilly Target as a monospecific or ADC), including all Manufacturing and Commercialization activities, in all cases, in accordance with the terms of this Agreement. With respect to each Lilly Target Pair for which [[Merus:Organization]] has delivered to Lilly a lead Collaboration Compound and the JSC-specified number of back-up Collaboration Compounds arising under the applicable Research Plan for such Research Program: # until ​, Lilly shall use Commercially Reasonable Efforts, at its own expense, to Develop and obtain Marketing Authorization ​ Product directed to each such Lilly Target Pair ​ in each of the United States, Japan, and at least two (2) of the [[Unknown Identifier]] Markets, and # following ​ arising from activities under this Agreement, Lilly shall use Commercially Reasonable Efforts to Commercialize such Product in each ​. Subject to the terms and conditions of this Agreement, including the foregoing sentence, all decisions concerning the Exploitation of Compounds and Products, including the clinical and regulatory strategy of Compounds and Products, the marketing and sales of Products, and the design, price, and promotion of Products, shall be at the sole discretion of Lilly.